Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F25%3AA2603AIE" target="_blank" >RIV/61988987:17110/25:A2603AIE - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/17512433.2025.2450257" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/17512433.2025.2450257</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/17512433.2025.2450257" target="_blank" >10.1080/17512433.2025.2450257</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care

Popis výsledku v původním jazyce

BackgroundThe cardioselective beta-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. Research design and methodsIn this study, trough serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. ResultsConcentrations were 1.3-122.9 mu g/L for metoprolol and 1.3-125.7 mu g/L for alpha-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and alpha-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF <= 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. ConclusionsMetoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and alpha-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing.

Název v anglickém jazyce

Analysis of serum concentrations of metoprolol and its metabolite α-hydroxymetoprolol in patients with heart failure with reduced ejection fraction: a pilot study in routine health care

Popis výsledku anglicky

BackgroundThe cardioselective beta-1 receptor antagonist metoprolol is used to treat heart failure. It is metabolized in the liver, primarily by cytochrome 2D6. Research design and methodsIn this study, trough serum concentrations of metoprolol and its metabolite alpha-hydroxymetoprolol were measured in patients with heart failure with reduced ejection fraction. ResultsConcentrations were 1.3-122.9 mu g/L for metoprolol and 1.3-125.7 mu g/L for alpha-hydroxymetoprolol, metabolic ratios were 0.11-98.32. The median weight-adjusted apparent clearance of metoprolol was 53.07 (range 3.24-500.0). Metoprolol and alpha-hydroxymetoprolol concentrations correlated with both daily dose and dose per kilogram of body weight. However, metoprolol concentrations at the same daily dose showed a wide variability. Patients taking 100 mg/day had significantly lower NT-proBNP values than those taking 25 or 50 mg/day. Patients with LVEF <= 35% versus > 35% used significantly lower daily doses and doses per kilogram of body weight, although metoprolol concentrations did not differ. A poor cytochrome 2D6 metabolizer phenotype was detected in two patients. ConclusionsMetoprolol concentrations showed a wide interindividual variability at the same daily dose. Simultaneous determination of metoprolol and alpha-hydroxymetoprolol concentrations could identify patients at risk of possible accumulation of metoprolol leading to intoxication or, conversely, patients at risk of underdosing.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EXPERT REVIEW OF CLINICAL PHARMACOLOGY

ISSN

1751-2433

e-ISSN

1751-2441

Svazek periodika

—

Číslo periodika v rámci svazku

1-2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

89-99

Kód UT WoS článku

001398961400001

EID výsledku v databázi Scopus

2-s2.0-85215326767